HC Wainwright Issues Optimistic Estimate for MLYS Earnings

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) – Equities researchers at HC Wainwright raised their Q3 2025 EPS estimates for shares of Mineralys Therapeutics in a research note issued on Thursday, October 30th. HC Wainwright analyst M. Caufield now forecasts that the company will post earnings per share of ($0.58) for the quarter, up from their prior estimate of ($0.74). HC Wainwright has a “Buy” rating and a $52.00 price target on the stock. The consensus estimate for Mineralys Therapeutics’ current full-year earnings is ($4.23) per share. HC Wainwright also issued estimates for Mineralys Therapeutics’ Q4 2025 earnings at ($0.61) EPS, FY2025 earnings at ($2.60) EPS, FY2026 earnings at ($2.37) EPS, FY2027 earnings at ($2.36) EPS, FY2028 earnings at ($0.39) EPS and FY2029 earnings at $2.09 EPS.

Mineralys Therapeutics (NASDAQ:MLYS) last posted its earnings results on Tuesday, August 12th. The company reported ($0.66) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.78) by $0.12.

Several other analysts have also issued reports on the stock. Wells Fargo & Company raised their price target on shares of Mineralys Therapeutics from $26.00 to $50.00 and gave the stock an “overweight” rating in a research report on Thursday, September 11th. The Goldman Sachs Group raised their price target on shares of Mineralys Therapeutics from $32.00 to $52.00 and gave the stock a “buy” rating in a research report on Tuesday, September 9th. Jefferies Financial Group raised their price target on shares of Mineralys Therapeutics from $15.00 to $26.00 and gave the stock a “hold” rating in a research report on Wednesday, September 3rd. Weiss Ratings restated a “sell (d-)” rating on shares of Mineralys Therapeutics in a research report on Wednesday, October 8th. Finally, Bank of America raised their price target on shares of Mineralys Therapeutics from $38.00 to $43.00 and gave the stock a “buy” rating in a research report on Thursday, August 28th. Five research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Mineralys Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $45.17.

Mineralys Therapeutics Trading Down 0.6%

NASDAQ:MLYS opened at $40.86 on Monday. Mineralys Therapeutics has a 1 year low of $8.24 and a 1 year high of $44.80. The firm’s fifty day simple moving average is $36.16 and its 200 day simple moving average is $22.12. The firm has a market capitalization of $2.71 billion, a PE ratio of -11.48 and a beta of 0.40.

Hedge Funds Weigh In On Mineralys Therapeutics

Several institutional investors have recently added to or reduced their stakes in MLYS. RA Capital Management L.P. raised its stake in shares of Mineralys Therapeutics by 26.7% in the first quarter. RA Capital Management L.P. now owns 6,147,280 shares of the company’s stock worth $97,619,000 after acquiring an additional 1,296,296 shares during the last quarter. SR One Capital Management LP raised its stake in shares of Mineralys Therapeutics by 55.1% in the first quarter. SR One Capital Management LP now owns 3,127,933 shares of the company’s stock worth $49,672,000 after acquiring an additional 1,111,111 shares during the last quarter. Jennison Associates LLC raised its stake in shares of Mineralys Therapeutics by 82.9% in the first quarter. Jennison Associates LLC now owns 1,979,033 shares of the company’s stock worth $31,427,000 after acquiring an additional 897,027 shares during the last quarter. Orbimed Advisors LLC bought a new position in shares of Mineralys Therapeutics in the second quarter worth about $10,288,000. Finally, Stempoint Capital LP raised its stake in shares of Mineralys Therapeutics by 605.3% in the second quarter. Stempoint Capital LP now owns 631,586 shares of the company’s stock worth $8,551,000 after acquiring an additional 756,586 shares during the last quarter. 84.46% of the stock is owned by institutional investors.

Insider Activity at Mineralys Therapeutics

In other news, Director Ra Capital Management, L.P. purchased 1,176,470 shares of the business’s stock in a transaction that occurred on Thursday, September 4th. The stock was purchased at an average cost of $25.50 per share, with a total value of $29,999,985.00. Following the acquisition, the director directly owned 5,456,521 shares of the company’s stock, valued at approximately $139,141,285.50. This trade represents a 27.49% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Jon Congleton sold 15,100 shares of Mineralys Therapeutics stock in a transaction dated Monday, October 13th. The shares were sold at an average price of $42.67, for a total transaction of $644,317.00. Following the transaction, the chief executive officer directly owned 831,305 shares of the company’s stock, valued at $35,471,784.35. This represents a 1.78% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 58,959 shares of company stock worth $2,098,393 in the last ninety days. Company insiders own 33.24% of the company’s stock.

Mineralys Therapeutics Company Profile

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.